Trials / Active Not Recruiting
Active Not RecruitingNCT05869227
Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
The Efficacy and Safety of Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma:Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 166 (actual)
- Sponsor
- XIANG YANQUN · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with toripalimab maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after receiving remission through chemotherapy combined with anti PD-1 monoclonal antibody standard regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Capecitabine/Placebo combined with toripalimab | Combined |
Timeline
- Start date
- 2023-04-28
- Primary completion
- 2027-12-20
- Completion
- 2027-12-20
- First posted
- 2023-05-22
- Last updated
- 2024-12-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05869227. Inclusion in this directory is not an endorsement.